CureDM
Latest round
- Series B
Last raised
- Nov 2006
Total raised
- $2.5M
Investors
- 2
About CureDM
CureDM, founded in 2004 in Wilmington, US, specializes in diabetes therapies.10 mn.CureDM, Inc. specializes in developing biopharmaceutical therapies aimed at reversing diabetes, with its core product being Human pro Islet Peptide (HIP2B). This peptide regenerates insulin-producing islets in the pancreas, promoting new islet differentiation from adult pancreatic progenitor cells.CureDM's revenue model is centered on partnerships and licensing agreements with established pharmaceutical companies. These firms handle the marketing and distribution of CureDM's proprietary peptide therapies, which generate revenue through upfront licensing fees, milestone payments for development, and royalties on product sales. The company aims to expand into new geographical markets, particularly in North America and select regions in Asia, by 2025. This strategic plan includes enhancing R&D efforts to bring innovative products to market and solidifying partnerships with pharmaceutical firms to facilitate successful commercialization.
Who invested in CureDM
2 investors across 1 round
See all investors in CureDM
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Nov 30, 2006
Amount
$2.5M
Investors
Questions about CureDM
Who invested in CureDM?
CureDM has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has CureDM raised?
CureDM has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did CureDM last raise money?
CureDM's most recent round on record is a Series B, in Nov 2006.
What does CureDM do?
CureDM, founded in 2004 in Wilmington, US, specializes in diabetes therapies.
Where is CureDM headquartered?
CureDM is headquartered in Wilmington, US.
Which VCs invest in companies like CureDM?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at CureDM's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like CureDM? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.